Bio-Techne Corp

$47.77
(as of Jun 3, 9:31 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Bio-Techne Corp

Stock Price
$47.77
Ticker Symbol
TECH
Exchange
NASDAQ

Industry Information for Bio-Techne Corp

Sector
Healthcare
Industry
Biotechnology

Company Description for Bio-Techne Corp

Country
USA
Full Time Employees
3,100

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Fundamentals for Bio-Techne Corp

Market Capitalization
$8,029,297,152
EBITDA
$309,534,016
Dividends per Share
$0.32
P/E Ratio
51.28
Forward P/E Ratio
22.52
Earnings per Share
$0.98
Earnings per Share Estimate Next Year
Profit Margin
13.22%
Shares Outstanding
158,088,000
Percent Owned by Insiders
1.05%
Percent Owned by Institutions
100.85%
52-Week High
52-Week Low

Technical Indicators for Bio-Techne Corp

50-Day Moving Average
200-Day Moving Average
RSI
51.34
2.05

Analyst Ratings for Bio-Techne Corp

Strong Buy
8
Buy
2
Hold
5
Sell
0
Strong Sell
0

News About Bio-Techne Corp

Jun 2, 2025, 11:33 PM EST
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. See more.
May 30, 2025, 12:47 AM EST
We came across a bullish thesis on Bio-Techne Corporation (TECH) on scuttleblurb’s Substack. See more.
May 29, 2025, 8:47 AM EST
Bio-Techne’s TECH GMP reagents, including GMP proteins and small molecules, remain a cornerstone of its cell therapy offering. See more.
May 29, 2025, 7:00 AM EST
MINNEAPOLIS, May 29, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: See more.